Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 54

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 54
---
459 |   |     |   |          5,378,456 |   |
| Working capital     |     | $ |         (5,696,776 | ) |     | $ |         (5,235,105 | ) |

Working capital deficit increased by $ 461,670 from September 30, 2024 to December 31, 2024, primarily due to increase in Derivative Liability.

Liquidity and Capital Resources

|                                                      |     | Quarter Ended |         |   |     |      |          |   |
|:-----------------------------------------------------|:----|--------------:|--------:|:--|:----|-----:|---------:|:--|
|                                                      |     |  December 31, |         |   |     |      |          |   |
|                                                      |     |          2024 |         |   |     | 2023 |          |   |
| Net cash used in operating activities                |     |             $ | (66,379 | ) |     |    $ | (162,336 | ) |
| Net cash provided by financing activities            |     |               |  65,799 |   |     |      |  165,797 |   |
| Net increase (decrease) in cash and cash equivalents |     |             $ |    (581 | ) |     |    $ |    3,460 |   |
| Cash, beginning of period                            |     |               |     716 |   |     |      |  121,037 |   |
| Cash, end of period                                  |     |             $ |     135 |   |     |    $ |  124,497 |   |

| 42 |

Operating Activities

Net cash used in operating activities for the quarter ended December 31, 2024 was $66,379, compared to $162,336, for the same period ended, 2023, a decrease of $96,256. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company during the quarter ended December 31, 2024 as compared to the same quarter ended 2023.

Financing Activities

Net cash generated by financing activities for the quarter ended December 31, 2024 was $65,799 which consisted of proceeds from notes payables.

Liquidity & Capital Resources Outlook

As of December 31, 2024, the Company had cash of $ 135